FindMyKOL
Clinical trialNCT06826742CompletedPhase 4Interventional

Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery

NCT06826742 is a phase 4 interventional trial sponsored by Mayo Clinic. As of 18 Nov 2026, it is completed. It studies Intrathecal Morphine and Intravenous line Methadone in Cesarean Delivery. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 12 Feb 2025 and a primary completion date of 14 Sept 2025.

SponsorMayo Clinic →Enrollment30Cesarean Delivery
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06826742
FieldValue
Registry IDNCT06826742
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorMayo Clinic
Enrollment30
Registered sites1
Countries1
ConditionsCesarean Delivery
DrugsIntrathecal Morphine and Intravenous line Methadone
Start12 Feb 2025
Primary completion14 Sept 2025
Study completion23 Sept 2025
Last update posted21 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Minnesota, United States1 site
  • Mayo Clinic in Rochester

    Rochester

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesota: 1 siteMN1WisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intrathecal MorphineIntravenous line Methadone
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06826742

Each answer restates registry values shown on this page.

What is NCT06826742?

NCT06826742 is a phase 4 interventional trial sponsored by Mayo Clinic. It studies Intrathecal Morphine and Intravenous line Methadone in Cesarean Delivery.

Who leads NCT06826742?

The registry names Emily E Sharpe, M.D. (principal investigator, Mayo Clinic) as the overall official.

Where does NCT06826742 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06826742 study?

The registered drug and biological interventions are Intrathecal Morphine and Intravenous line Methadone.

When did NCT06826742 end?

The registry lists a primary completion date of 14 Sept 2025 and a study completion date of 23 Sept 2025. The sponsor last updated the record on 21 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.